نتائج البحث - "Caroline Nickner"

1

Data from Randomized, Placebo-Controlled, Phase II Study of Veliparib in Combination with Carboplatin and Paclitaxel for Advanced/Metastatic Non–Small Cell Lung Cancer

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::45e7ce0aeb342f5774b9143be1c1edd9
https://doi.org/10.1158/1078-0432.c.6526571.v1

2

Supplemental Materials from Randomized, Placebo-Controlled, Phase II Study of Veliparib in Combination with Carboplatin and Paclitaxel for Advanced/Metastatic Non–Small Cell Lung Cancer

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::62499efaffeb259872b1608c05230ee5
https://doi.org/10.1158/1078-0432.22467197

3

Rovalpituzumab Tesirine as a Maintenance Therapy After First-Line Platinum-Based Chemotherapy in Patients With Extensive-Stage–SCLC: Results From the Phase 3 MERU Study

مصطلحات موضوعية: 0301 basic medicine, Pulmonary and Respiratory Medicine, medicine.medical_specialty, Immunoconjugates, Lung Neoplasms, Maintenance, medicine.medical_treatment, Population, Peripheral edema, DLL3, Phase 3, Antibodies, Monoclonal, Humanized, Placebo, Rovalpituzumab tesirine, Gastroenterology, 03 medical and health sciences, 0302 clinical medicine, Double-Blind Method, Maintenance therapy, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Clinical endpoint, Humans, education, Platinum-based chemotherapy, Platinum, Benzodiazepinones, Chemotherapy, education.field_of_study, Small cell lung cancer, business.industry, Middle Aged, Confidence interval, 3. Good health, 030104 developmental biology, Oncology, 030220 oncology & carcinogenesis, medicine.symptom, business

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::86ac72b3b5a5194730ae4d89381fe419
http://hdl.handle.net/10852/91515

4

Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study

المساهمون: Medical Oncology

المصدر: Annals of Oncology, 29(1), 154-161. Elsevier Ltd.
Han, H S, Diéras, V, Robson, M, Palácová, M, Marcom, P K, Jager, A, Bondarenko, I, Citrin, D, Campone, M, Telli, M L, Domchek, S M, Friedlander, M, Kaufman, B, Garber, J E, Shparyk, Y, Chmielowska, E, Jakobsen, E H, Kaklamani, V, Gradishar, W, Ratajczak, C K, Nickner, C, Qin, Q, Qian, J, Shepherd, S P, Isakoff, S J & Puhalla, S 2018, ' Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer : Randomized phase II study ', Annals of Oncology, vol. 29, no. 1, pp. 154-161 . https://doi.org/10.1093/annonc/mdx505

مصطلحات موضوعية: 0301 basic medicine, Oncology, Male, medicine.medical_treatment, Genes, BRCA2, Genes, BRCA1, Phases of clinical research, Placebos, chemistry.chemical_compound, 0302 clinical medicine, Single-Blind Method, Neoplasm Metastasis, PARP inhibitors, Benzimidazoles/administration & dosage, Temozolomide/administration & dosage, Hematology, Middle Aged, Metastatic breast cancer, Chemotherapy regimen, Neoplasm Recurrence, Local/drug therapy, 030220 oncology & carcinogenesis, Female, medicine.drug, Adult, medicine.medical_specialty, Veliparib, 03 medical and health sciences, Young Adult, Breast cancer, Breast Neoplasms/drug therapy, SDG 3 - Good Health and Well-being, Internal medicine, Paclitaxel/administration & dosage, medicine, Temozolomide, Humans, Germ-Line Mutation, Platinum, Aged, Chemotherapy, business.industry, Antineoplastic Combined Chemotherapy Protocols/adverse effects, Carboplatin/administration & dosage, Breast Neoplasms, Male/drug therapy, medicine.disease, Carboplatin, 030104 developmental biology, chemistry, business